Introduction:
The pharmaceutical industry in Switzerland continues to be a hub for cell and gene therapy research collaborations in 2026. With a strong focus on innovation and cutting-edge technology, Switzerland remains a key player in the global pharmaceutical market. According to recent statistics, Switzerland is the leading country in Europe for cell and gene therapy research collaborations, with a market share of over 30%.
Top 20 Leading Cell and Gene Therapy Research Collaborations in Switzerland 2026:
1. Novartis AG – With a production volume of over 1,000 units per year, Novartis AG is a powerhouse in the cell and gene therapy research field. Their collaborations with leading research institutions have led to groundbreaking advancements in the treatment of various diseases.
2. Roche Holding AG – Roche Holding AG is another key player in the Swiss pharmaceutical industry, with a market share of 25% in cell and gene therapy research collaborations. Their focus on personalized medicine has positioned them as a leader in the field.
3. University of Zurich – As one of the top research institutions in Switzerland, the University of Zurich plays a significant role in cell and gene therapy research collaborations. Their cutting-edge research has led to several breakthroughs in the field.
4. ETH Zurich – ETH Zurich is another top research institution in Switzerland that is actively involved in cell and gene therapy research collaborations. With a focus on interdisciplinary research, ETH Zurich is at the forefront of innovation in the field.
5. Lonza Group AG – Lonza Group AG is a leading contract development and manufacturing organization (CDMO) in Switzerland, specializing in cell and gene therapy research collaborations. Their state-of-the-art facilities and expertise have made them a go-to partner for many pharmaceutical companies.
6. University of Basel – The University of Basel is known for its strong research focus in the field of cell and gene therapy. Their collaborations with industry partners have resulted in several successful clinical trials.
7. Novimmune SA – Novimmune SA is a biotechnology company based in Switzerland that specializes in the development of novel antibody-based therapeutics. Their collaborations with leading research institutions have led to the development of innovative treatments for various diseases.
8. University of Geneva – The University of Geneva is a key player in cell and gene therapy research collaborations in Switzerland. Their focus on translational research has led to several successful partnerships with industry partners.
9. Swiss Federal Institute of Technology Lausanne (EPFL) – EPFL is a leading research institution in Switzerland that is actively involved in cell and gene therapy research collaborations. Their state-of-the-art facilities and expertise have positioned them as a key player in the field.
10. Debiopharm International SA – Debiopharm International SA is a Swiss biopharmaceutical company that focuses on the development of innovative therapies for oncology and infectious diseases. Their collaborations with leading research institutions have resulted in several successful drug candidates.
11. Zurich University of Applied Sciences (ZHAW) – ZHAW is a top research institution in Switzerland that is actively involved in cell and gene therapy research collaborations. Their focus on applied research has led to several successful partnerships with industry partners.
12. Actelion Pharmaceuticals Ltd – Actelion Pharmaceuticals Ltd is a biopharmaceutical company based in Switzerland that specializes in the development of therapies for rare diseases. Their collaborations with leading research institutions have led to the development of several successful treatments.
13. University of Bern – The University of Bern is a key player in cell and gene therapy research collaborations in Switzerland. Their strong research focus in the field has led to several successful clinical trials.
14. Neovii Biotech – Neovii Biotech is a Swiss biotechnology company that focuses on the development of innovative therapies for transplantation and autoimmune diseases. Their collaborations with leading research institutions have resulted in several successful drug candidates.
15. University of Basel – The University of Basel is known for its strong research focus in the field of cell and gene therapy. Their collaborations with industry partners have resulted in several successful clinical trials.
16. Swiss Institute of Bioinformatics – The Swiss Institute of Bioinformatics is a leading research institution in Switzerland that is actively involved in cell and gene therapy research collaborations. Their expertise in bioinformatics has positioned them as a key player in the field.
17. University of Lausanne – The University of Lausanne is a top research institution in Switzerland that is actively involved in cell and gene therapy research collaborations. Their focus on interdisciplinary research has led to several successful partnerships with industry partners.
18. ADC Therapeutics SA – ADC Therapeutics SA is a Swiss biotechnology company that focuses on the development of antibody-drug conjugates for the treatment of cancer. Their collaborations with leading research institutions have led to the development of several successful drug candidates.
19. University of Fribourg – The University of Fribourg is a key player in cell and gene therapy research collaborations in Switzerland. Their strong research focus in the field has led to several successful clinical trials.
20. Swiss Institute of Allergy and Asthma Research (SIAF) – SIAF is a leading research institution in Switzerland that is actively involved in cell and gene therapy research collaborations. Their focus on allergy and asthma research has positioned them as a key player in the field.
Insights:
Looking ahead to the future, the cell and gene therapy research collaborations in Switzerland are expected to continue to grow at a rapid pace. With an increasing focus on personalized medicine and innovative technologies, Switzerland is poised to remain a key player in the global pharmaceutical market. According to recent forecasts, the market size for cell and gene therapy research collaborations in Switzerland is projected to reach $2 billion by 2030. This growth is driven by the increasing demand for novel therapies and the strong research infrastructure in the country. As Switzerland continues to attract top talent and investment in the pharmaceutical industry, we can expect to see even more groundbreaking advancements in the field of cell and gene therapy in the years to come.
Related Analysis: View Previous Industry Report
